SEATTLE--(BUSINESS WIRE)--Feb. 26, 2018--
Omeros Corporation (NASDAQ: OMER) today announced that the company will
issue its fourth quarter and year-end 2017 financial results for the
period ended December 31, 2017, on Thursday, March 1, 2018, after the
market closes. Omeros management will host a conference call and webcast
that day at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss
the financial results.
Conference Call Details
To access the live conference call via phone, please dial (844) 831-4029
from the United States and Canada or (920) 663-6278 internationally. The
participant passcode is 1759244. Please dial in approximately 10 minutes
prior to the start of the call. A telephone replay will be available for
one week following the call and may be accessed by dialing (855)
859-2056 from the United States and Canada or (404) 537-3406
internationally. The replay passcode is 1759244.
To access the live and subsequently archived webcast of the conference
call, go to Omeros’ website at www.omeros.com
and go to “Events” under the Investors section of the website. Please
connect to the website at least 15 minutes prior to the call to allow
for any software download that may be necessary.
About Omeros Corporation
Omeros is a commercial-stage biopharmaceutical company committed to
discovering, developing and commercializing small-molecule and protein
therapeutics for large-market as well as orphan indications targeting
inflammation, complement-mediated diseases and disorders of the central
nervous system. The company’s drug product OMIDRIA®
(phenylephrine and ketorolac intraocular solution) 1% / 0.3% is marketed
for use during cataract surgery or intraocular lens (IOL) replacement to
maintain pupil size by preventing intraoperative miosis (pupil
constriction) and to reduce postoperative ocular pain. In the European
Union, the European Commission has approved OMIDRIA for use in cataract
surgery and other IOL replacement procedures to maintain mydriasis
(pupil dilation), prevent miosis (pupil constriction), and to reduce
postoperative eye pain. Omeros has multiple Phase 3 and Phase 2
clinical-stage development programs focused on: complement-associated
thrombotic microangiopathies; complement-mediated
glomerulonephropathies; Huntington’s disease and cognitive impairment;
and addictive and compulsive disorders. In addition, Omeros has a
diverse group of preclinical programs and a proprietary G
protein-coupled receptor (GPCR) platform through which it controls 54
new GPCR drug targets and corresponding compounds, a number of which are
in preclinical development. The company also exclusively possesses a
novel antibody-generating platform.
View source version on businesswire.com: http://www.businesswire.com/news/home/20180226005781/en/
Source: Omeros Corporation
Cook Williams Communications, Inc.
Jennifer Cook Williams,
360.668.3701
Investor and Media Relations
